Altamira Therapeutics Ltd. (CYTO)

NASDAQ: CYTO · IEX Real-Time Price · USD

1.200

-0.140 (-10.45%)

At close: Jul 19, 2024, 4:00 PM

1.180

-0.020 (-1.67%)

Pre-market: Jul 22, 2024, 9:10 AM EDT

Altamira Therapeutics Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-3.87	-3.87	-26.53	-17.06	-8.2	-6.63	Upgrade
Depreciation & Amortization	0.12	0.12	0.12	0.08	0.02	0.03	Upgrade
Share-Based Compensation	0.38	0.38	0.34	1.21	0.37	0.23	Upgrade
Other Operating Activities	-8.14	-8.14	17.38	2.1	2.97	-2.02	Upgrade
Operating Cash Flow	-11.51	-11.51	-8.68	-13.67	-4.84	-8.39	Upgrade
Capital Expenditures	0	0	0	0	0	-0.06	Upgrade
Acquisitions	1.43	1.43	0	0	0	0	Upgrade
Change in Investments	0.01	0.01	0	-0.18	0	0	Upgrade
Other Investing Activities	0	0	-2.14	-3.33	-2.31	-2.94	Upgrade
Investing Cash Flow	1.44	1.44	-2.14	-3.51	-2.31	-3	Upgrade
Share Issuance / Repurchase	10.51	10.51	3.96	6.84	16.07	9.79	Upgrade
Debt Issued / Paid	1.05	1.05	5.92	-0.07	1.52	-1.46	Upgrade
Other Financing Activities	-0.93	-0.93	-0.05	-0.16	-0.64	-0.95	Upgrade
Financing Cash Flow	10.62	10.62	9.83	6.61	16.96	7.38	Upgrade
Exchange Rate Effect	0.05	0.05	0.02	0.29	0.07	0.01	Upgrade
Net Cash Flow	0.56	0.56	-0.99	-10.56	9.8	-4.02	Upgrade
Free Cash Flow	-11.51	-11.51	-8.68	-13.67	-4.84	-8.46	Upgrade
Free Cash Flow Per Share	-28.94	-28.94	-203.54	-400.87	-382.95	-1804.37	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).